Vaxart, Inc. reports positive data from Phase 1 clinical trial for its second-generation oral pill norovirus vaccine constructs, showing a significant increase in fecal IgA response over baseline. These results suggest stronger immunological responses compared to first-generation constructs, potentially leading to improved efficacy. The company plans to conduct a Phase 2b trial in 2025, aiming to address the lack of an approved norovirus vaccine, a major cause of gastroenteritis globally with a significant economic impact.

Reference 1: Flitter BA, Gillard J, Greco SN et al. An oral norovirus vaccine generates mucosal immunity and reduces viral shedding in a phase 2 placebo-controlled challenge study. 2025;17(798):eadh9906.

Read more at GlobeNewswire: Vaxart Reports Additional Phase 1 Data Supporting the